Search

Your search keyword '"Philip Tagari"' showing total 56 results

Search Constraints

Start Over You searched for: Author "Philip Tagari" Remove constraint Author: "Philip Tagari"
56 results on '"Philip Tagari"'

Search Results

1. Structure-guided Discovery of Dual-recognition Chemibodies

2. Metal-Free Polymer-Based Affinity Medium for Selective Purification of His6-Tagged Proteins

3. Nanoscale integration of single cell biologics discovery processes using optofluidic manipulation and monitoring

4. Rapid single B cell antibody discovery using nanopens and structured light

5. Functional arrays of human pluripotent stem cell-derived cardiac microtissues

6. Function-based high-throughput screening for antibody antagonists and agonists against G protein-coupled receptors

7. Cover Image, Volume 116, Number 9, September 2019

8. Functional arrays of human pluripotent stem cell-derived cardiac microtissues

9. Structure-guided discovery of dual recognition chemibodies

10. Kinetic characterization and identification of a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 using a time-resolved fluorescence resonance energy transfer-based assay technology

11. Discovery of novel hydroxy-thiazoles as HIF-α prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation

12. Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents

13. (4-Piperidinylphenyl)aminoethyl amides as a novel class of non-covalent cathepsin K inhibitors

14. Epitope discovery for a synthetic polymer nanoparticle: A new strategy for developing a peptide tag

15. Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors

16. Analysis of Prostaglandin G/H Synthase-2 Inhibition Using Peroxidase-Induced Luminol Luminescence

17. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells

18. Synthesis and biological evaluation of both enantiomers of L-761,000 as inhibitors of cyclooxygenase 1 and 2

19. From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors

20. Synthesis and biological evaluation of 2,3-diarylthiophenes as selective cox-2 inhibitors. part II: Replacing the heterocycle

21. Epitope-labeled Soluble Human Interleukin-5 (IL-5) Receptors

22. Synthesis and biological evaluation of 2,3-diarylthiophenes as selective Cox-2 and Cox-1 inhibitors

23. Levels of Peptidoleukotriene E4 Are Elevated in Active Crohnʼs Disease

24. A Single-Step Purification of Biologically Active Recombinant Human Interleukin-5 from a Baculovirus Expression System

25. Antiasthmatic effects of a leukotriene biosynthesis inhibitor (MK-0591) in allergic dogs

26. Measurement of canine urinary thromboxanes by GC-MC and HPLC-RIA

27. Assessment of thein vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors

28. A rapid biochemical method for measuring antigen-induced pulmonary eosinophil margination in allergic guinea pigs

29. Activation of Human Eosinophils and Differentiated HL-60 Cells by lnterleukin-5

30. ChemInform Abstract: Substituted Thiopyrano(2,3,4-c,d)indoles as Potent, Selective, and Orally Active Inhibitors of 5-Lipoxygenase. Synthesis and Biological Evaluation of L-691,816

31. ChemInform Abstract: Synthesis and Biological Evaluation of 2,3-Diarylthiophenes as Selective Cox-2 and Cox-1 Inhibitors

32. ChemInform Abstract: Synthesis and Biological Evaluation of 2,3-Diarylthiophenes as Selective COX-2 Inhibitors. Part 2. Replacing the Heterocycle

33. Leukotriene D receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma

34. Urinary Leukotriene E4Concentrations Increase after Aspirin Challenge in Aspirin-sensitive Asthmatic Subjects

35. Eosinophil-eicosanoid interactions: inhibition of eosinophil chemotaxis in vivo by a LTD4-receptor antagonist

36. BIO-fully automated sample treatment high-performance liquid chromatography and radioimmunoassay for leukotriene E4 in human urine from asthmatics

37. Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein

38. New 'chemical probes' to examine the role of the hFPRL1 (or ALXR) receptor in inflammation

39. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits

40. Quantitation of eosinophil Major Basic Protein cytotoxicity to rodent respiratory epithelium

41. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor

42. Quinolines as potent 5-lipoxygenase inhibitors: synthesis and biological profile of L-746,530

43. Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010

44. From Indomethacin to a Selective Cox-2 Inhibitor

45. Effect of altitude on urinary leukotriene (LT) E4 excretion and airway responsiveness to histamine in children with atopic asthma

46. Effect of FLAP antagonist MK-0591 on leukotriene production and ozone-induced airway responses in dogs

47. Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects

48. Reduced nonspecific bronchial reactivity and decreased airway response to antigen challenge in atopic asthmatic patients treated with the inhaled leukotriene D4 antagonist, L-648,051

49. Urinary LTE4 excretion in antigen-provoked asthmatic patients treated with the inhaled LTD4 antagonist, L-648,051

50. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor

Catalog

Books, media, physical & digital resources